Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2002
|
| gptkbp:approvedBy |
gptkb:United_States
gptkb:FDA |
| gptkbp:ATCCode |
H05AA02
|
| gptkbp:brand |
Forteo
Forsteo |
| gptkbp:CASNumber |
52232-67-4
|
| gptkbp:category |
parathyroid hormone analog
anabolic agent for bone bone formation agent |
| gptkbp:chemicalFormula |
C181H291N55O51S2
|
| gptkbp:contraindication |
gptkb:hypercalcemia
gptkb:Paget's_disease bone metastases unexplained elevations of alkaline phosphatase prior radiation therapy involving the skeleton |
| gptkbp:discoveredBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:eliminatedIn |
renal
|
| gptkbp:form |
solution for injection
|
| gptkbp:halfLife |
about 1 hour
|
| https://www.w3.org/2000/01/rdf-schema#label |
teriparatide
|
| gptkbp:KEGGID |
D06053
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:maximumDurationOfUse |
2 years
|
| gptkbp:mechanismOfAction |
parathyroid hormone receptor agonist
stimulates osteoblast activity |
| gptkbp:notRecommendedFor |
adolescents
children |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescribes |
patients at high risk of fracture
|
| gptkbp:proteinSequence |
first 34 amino acids of human parathyroid hormone
|
| gptkbp:PubChem_CID |
16129668
DB06285 |
| gptkbp:riskFactor |
osteosarcoma (in animal studies)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
gptkb:hypercalcemia
nausea dizziness leg cramps |
| gptkbp:storage |
refrigerated
|
| gptkbp:UNII |
Q7Z4601902
|
| gptkbp:usedFor |
gptkb:bone
glucocorticoid-induced osteoporosis treatment of osteoporosis in men treatment of osteoporosis in postmenopausal women |
| gptkbp:bfsParent |
gptkb:parathyroid_hormone
|
| gptkbp:bfsLayer |
6
|